Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

• Status: Completed
• Trial end date: 2013-12-01

Summary

study objectives are to compare the efficacy, safety and tolerability of two doses of MG01CI (1400 mg and 700 mg) to Placebo for the treatment of symptoms in adults diagnosed with PI-ADHD.

subjects will be randomly assigned in a 1:1:1 ratio to one of three treatment sequences as follows:

1. week 1:1400 mg, week 2:700 mg, week 3:placebo

2. week 1:700 mg,week 2: placebo,week 3:1400 mg

3. week 1: placebo, week2:1400 mg, week 3 700 mg

The study will consist of three periods: a screening period of up to one week, a 3-week double-blind treatment period, and a one-week safety follow-up period.

• Phase: Phase 2

Details

• Lead Sponsor: Alcobra Ltd.
• Treatments: Metadoxine; Pyridoxine